Omnicell (NASDAQ: OMCL) reported Q1 EPS of $0.61, $0.20 better than the analyst estimate of $0.41. Revenue for the quarter came in at $202.5 million versus the consensus estimate of $199.72 million.

"We believe that customers and the market are embracing our Autonomous Pharmacy vision and the impact that advanced automation, data intelligence, and expert services will have on patient care," said Randall A. Lipps, chairman, president, chief executive officer, and founder of Omnicell. "Our solutions are designed to drive improvement in patient and provider outcomes in a variety of healthcare settings across the continuum of care, with medication management automation becoming central to their success."

GUIDANCE:

Omnicell sees Q2 2019 EPS of $0.61-$0.66, versus the consensus of $0.56. Omnicell sees Q2 2019 revenue of $211-217 million, versus the consensus of $212.74 million.

Omnicell sees FY2019 EPS of $2.62-$2.82, versus the consensus of $2.51. Omnicell sees FY2019 revenue of $880-900 million, versus the consensus of $890.22 million.

For earnings history and earnings-related data on Omnicell (OMCL) click here.